Patel S, Hutson P H
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
Eur J Pharmacol. 1996 Dec 19;317(2-3):197-204. doi: 10.1016/s0014-2999(96)00716-9.
Central administration of galanin dose-dependently (minimum effective dose, M.E.D. = 1 nmol) blocked the hypothermia induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.5 mg/kg s.c.), in mice. This inhibitory effect was reversed by pretreatment with the galanin receptor antagonist galantide (0.3 nmol) and also by pretreatment with the ATP-sensitive potassium channel blockers glibenclamide (10 nmol) and gliquidone (10 nmol). The hypothermic response to 8-OH-DPAT was also blocked by the 5-HT1A receptor antagonist (N-(2,4(2-methoxyphenyl)-1-piperazinyl)ethyl-N-(2-pyridinyl)cyclohexane, (WAY 100,635, M.E.D. = 0.01 mg/kg s.c.), and the centrally acting muscarinic receptor antagonist scopolamine (M.E.D. = 10 mg/kg i.p.) but not the peripheral muscarinic receptor antagonist N-methylscopolamine. 8-OH-DPAT (0.5 mg/kg s.c.) also decreased cortical and hypothalamic 5-HT (5-hydroxytryptamine, serotonin) metabolism, an effect which was not blocked by pretreatment with galanin (0.3-3 nmol intracerebroventricular, i.c.v.). Neither did galanin (0.03-3 nmol/5 microliters i.c.v.) affect basal 5-HT metabolism in these brain regions. Furthermore, pretreatment in vitro of mouse cortical membranes with galanin (10 or 1000 nM) had no effect on 5-HT1A receptor affinity, Bmax or pharmacology determined using [3H]8-OH-DPAT. These results suggest that the inhibition of 8-OH-DPAT induced hypothermia by galanin is probably not mediated by an interaction with 5-HT1A receptors but more likely by blocking the indirect activation by 8-OH-DPAT of central cholinergic pathways involved in temperature regulation.
在小鼠中,向中枢给予甘丙肽呈剂量依赖性地(最小有效剂量,M.E.D. = 1纳摩尔)阻断了由5-羟色胺1A(5-HT1A)受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT,0.5毫克/千克,皮下注射)诱导的体温过低。用甘丙肽受体拮抗剂加兰他肽(0.3纳摩尔)预处理以及用ATP敏感性钾通道阻滞剂格列本脲(10纳摩尔)和格列喹酮(10纳摩尔)预处理可逆转这种抑制作用。5-HT1A受体拮抗剂(N-(2,4-(2-甲氧基苯基)-1-哌嗪基)乙基-N-(2-吡啶基)环己烷,(WAY 100,635,M.E.D. = 0.01毫克/千克,皮下注射)以及中枢作用的毒蕈碱受体拮抗剂东莨菪碱(M.E.D. = 10毫克/千克,腹腔注射)也可阻断对8-OH-DPAT的体温过低反应,但外周毒蕈碱受体拮抗剂N-甲基东莨菪碱则不能。8-OH-DPAT(0.5毫克/千克,皮下注射)还降低了皮质和下丘脑的5-羟色胺(5-HT,5-羟色胺,血清素)代谢,用甘丙肽(0.3 - 3纳摩尔,脑室内注射,i.c.v.)预处理并不能阻断这种作用。甘丙肽(0.03 - 3纳摩尔/5微升,脑室内注射)也不影响这些脑区的基础5-HT代谢。此外,用甘丙肽(10或1000纳摩尔)在体外预处理小鼠皮质膜对使用[3H]8-OH-DPAT测定的5-HT1A受体亲和力、最大结合容量(Bmax)或药理学没有影响。这些结果表明,甘丙肽对8-OH-DPAT诱导的体温过低的抑制作用可能不是通过与5-HT1A受体相互作用介导的,而更可能是通过阻断8-OH-DPAT对参与体温调节的中枢胆碱能途径的间接激活来实现的。